Clinical Trial Results:
Efficacy and safety of intra-articular multiple doses of 500 µg icatibant including 40 mg triamcinolone as calibrator in a randomized, double-blind, parallel-group, placebo-controlled 13-week multi-centre study in patients with symptomatic knee osteoarthritis*
*After the clinical start of the study, an extension of the follow-up period has been established by amendment n°2, extending the observation period by further 26 weeks; thus, the overall study duration will become totally 39 weeks.
Summary
|
|
EudraCT number |
2005-003258-87 |
Trial protocol |
DE AT SI LT CZ SK |
Global completion date |
31 Jul 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
01 May 2016
|
First version publication date |
01 May 2016
|
Other versions |
|
Summary report(s) |
DRI6091 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.